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The HPV Vaccination in Japan 
Issues and Options 
Rose Wilson, Pauline Paterson, and Heidi J. Larson1 
 
Introduction 
The human papillomavirus (HPV) is the cause of most cervical cancers, which is why 
the 2006 licensing of an effective HPV vaccine was widely welcomed as an important 
advance for global public health. In Japan, the HPV vaccine (Cervarix®) was licensed 
in October 2009; the following year, the Japanese government began subsidizing its 
delivery, and in April 2013, the HPV vaccine was added to the government of Japan’s 
list of routine vaccinations. Yet, in June 2013, the Japanese Ministry of Health, Labor, 
and Welfare (MHLW) suspended its recommendation for HPV vaccination after a 
series of highly publicized alleged adverse events following immunization stoked 
public doubts about the vaccine’s safety. The HPV vaccine has been in a confusing 
state of limbo in Japan ever since: it is still available for free, yet lacking the ministry’s 
active recommendation for its use. 
This paper explores how Japan’s response to HPV vaccine concerns has been 
perceived across the globe and illustrates examples in other countries that have faced 
similar challenges, such as Australia, France, India, and the United Kingdom. Given 
HPV’s recognized importance in causing multiple cancers, and the vaccine’s proven 
efficacy against it, we believe it is essential to maintain the public’s trust in the 
vaccine. The paper concludes with recommendations to the Japanese government 
toward that end.  
HPV and Cervical Cancer: A Global Overview 
According to the World Health Organization (WHO), “cervical cancer is the second 
most common cancer in women in the world and the third greatest cause of death 
from cancer in women.”2 Every year, about 270, 000 women die of cervical cancer, 
over 85 percent of whom are in developing countries3 (see Appendix 14). 
Seventy percent of cervical cancers are caused by two strains of human 
papillomavirus: HPV 16 and 18. HPV is mainly spread through skin-to-skin sexual 
1 Rose Wilson is a research assistant, Pauline Paterson a research fellow, and Heidi J. Larson a senior 
lecturer in the Department of Infectious Disease Epidemiology at the London School of Hygiene & 
Tropical Medicine in London, England. The authors would also like to acknowledge the contribution of 
Sharon Hanley, Hokkaido University, in preparing the document. 
2 World Health Organization (WHO), “Human papillomavirus (HPV) and cervical cancer,” 2013, 
http://www.who.int/mediacentre/factsheets/fs380/en/#. 
3 International Agency for Research on Cancer, “GLOBOCAN 2012: Estimated Cancer Incidence, Mortality 
and Prevalence Worldwide in 2012,” 2012, http://globocan.iarc.fr/Pages/Map.aspx#. 
4 WHO, “Human papillomavirus (HPV) and cervical cancer.” 
| 1 
                                                 
contact; both women and men can be infected. Currently, there are two vaccines that 
protect against these strains of HPV: Cervarix® and Gardasil®. The vaccines are 
delivered in a series of three shots over six months, and work best when received 
before the vaccine recipient is sexually active. 
Initial indications are that the HPV vaccine is exceptionally effective. A study released 
by the U.S. Centers for Disease Control and Prevention in June 2013 found that the 
prevalence of these cancer-causing HPV strains had dropped by 56 percent among 
teen girls since the vaccine’s introduction in 2006. Moreover, although the HPV 
vaccine was initially licensed to address the global burden of cervical cancer, studies 
have found that HPV is also related to vulvar, vaginal, penile, anal, and oropharyngeal 
cancers and cancer-related deaths; and significant morbidity from external genital 
lesions.5 The vaccine can thus play a meaningful role in preventing these cancers and 
mitigating these health threats as well. 
HPV vaccines are currently licensed for use in 128 countries—nearly triple the 45 
countries in which it had been licensed at the end of 2012.6 Recommendations for HPV 
vaccination exist for females in 57 countries and for males in 6 countries and national 
funding for vaccination of girls and boys is provided in 54 and 2 countries, 
respectively.  
Since this is a relatively new vaccine, there are no global vaccination coverage 
estimates yet; however, over 40 million doses of the HPV vaccine have been given 
worldwide.7 In Australia, Scotland, and Rwanda, HPV vaccination coverage (licensed 
in 2007) is more than 80 percent for the first dose of the HPV vaccine and 70 percent 
for all three doses.8 
Over 26,000 subjects from five continents have been enrolled in clinical studies 
regarding the HPV vaccine. This includes two major randomized, double-blind, 
placebo-controlled trials (FUTURE I and FUTURE II for the Gardasil vaccine and 
PATRICIA (PApilloma TRIal against Cancer In young Adults), which measured vaccine 
efficacy against CIN3+ (grade three or greater cervical intraepithelial neoplasia) and 
adenocarcinoma, for the Cervarix vaccine).9 These trials have allowed investigation of 
the effects of race and region on the efficacy and safety of the vaccine. Importantly, 
5 M. A. Kane, B. Serrano, S. de Sanjosé, and S. Wittet, “Implementation of Human Papillomavirus 
Immunization in the Developing World,” Vaccine 30 (2012): F192–F200. 
6 WHO, “Global Immunization Data,” February 2014, 
http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf?ua=1. 
7 Ontario Ministry of Health and Long-Term Care, “Ontario’s HPV Vaccination Program,” 2014, 
http://www.health.gov.on.ca/en/ms/hpv/hpv_vaccine.aspx#skipnav. 
8 E. Crowe et al., “Effectiveness of Quadrivalent Human Papillomavirus Vaccine for the Prevention of 
Cervical Abnormalities: Case-control Study Nested within a Population Based Screening Programme in 
Australia,” BMJ 348 (March 2014): g1458, http://dx.doi.org/10.1136/bmj.g1458; U.S. Centers for Disease 
Control and Prevention, “New Study Shows HPV Vaccine Helping Lower HPV Infection Rates in Teen 
Girls,” 2013, http://www.cdc.gov/media/releases/2013/p0619-hpv-vaccinations.html; ISD Scotland, “HPV 
Immunisation Uptake Statistics,” 2013, https://isdscotland.scot.nhs.uk/Health-Topics/Child-
Health/Publications/2013-09-24/HPV-Report-September-2013.pdf?58488100768. 
9 M. Lehtinen et al., “Overall Efficacy of HPV-16/18 AS04-Adjuvanted Vaccine against Grade 3 or Greater 
Cervical Intraepithelial Neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA 
trial,” Lancet Oncology 13 (2012): 89–99. 
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subgroup analysis has demonstrated that the efficacy, immunogenicity, and safety of 
the HPV vaccine do not differ between race and region.10 
Still, despite its proven benefits, the HPV vaccine brings challenges. First, the HPV 
vaccine is relatively complex to introduce. Because it is given in adolescence, it needs 
a different location to optimize delivery as most childhood vaccines happen during 
visits to the doctors, whereas by the time a child is in adolescence, s/he no longer has 
regular check-ups (this could be addressed through school-based programs). Timing 
also matters. Because effectiveness depends on three shots in six months, completing 
the HPV vaccine series demands a real commitment from parents. In addition, as the 
vaccine prevents a sexually transmitted infection (STI), it evokes the moral judgments 
and religious and cultural taboos that come with discussing and addressing sexual 
behavior. Therefore, some health professionals11 have been reluctant about 
vaccination, questioning whether it may “send the wrong message” to teens by 
seeming to condone premarital sex. Research, however, has confirmed that teens who 
have received the HPV vaccine are not more sexually active than their peers.12  
Summary of the HPV Vaccine Experience in Japan 
In Japan, cervix uteri cancer is the cancer of the fifth-highest incidence for women 
(see Figure 1), while the rate of Pap tests, which screen for this cancer, are low at 
around 25.4 percent13 compared to 78.3 percent in the United Kingdom.14 
In addition, oropharyngeal cancers rose dramatically in Japan between 1990 and 2000 
(see Appendix 2)15; while, over the past 10 years, an average of 5,955 cases of genital 
warts have been reported annually, with men having a consistently higher number of 
reported cases than women. Genital warts cases are reported in men of all ages, 
although the majority occur between the ages of 20 and 40 years.16  
Approximately 67.1 percent of cervical cancers in Japan are considered related to HPV 
types 16 and 18. The prevalence of HPV 16 and 18 infections are as high in Japan as in 
the United States and Europe. However, it has been suggested that the number of  
10 H. Yoshikawa et al., “Efficacy of Quadrivalent Human Papillomavirus (types 6, 11, 16 and 18) Vaccine 
(GARDASIL) in Japanese Women Aged 18–26 Years,” Cancer Science 104 (2013). 
11 H. J. Larson, “The uptake of Human Papillomavirus Vaccination: The Power of Beliefs,” International 
Journal of Epidemiology 42 (2013): 908–10. 
12 N. C. Liddon, J. S. Leichliter, and L. E. Markowitz, “Human Papillomavirus Vaccine and Sexual Behavior 
among Adolescent and Young Women,” American Journal of Preventive Medicine 42 (2012): 44–52. 
13 T. Hoshino et al., “Does Removal of Out-of-pocket Costs for Cervical and Breast Cancer Screening Work? 
A Quasi-experimental Study to Evaluate the Impact on Attendance, Attendance Inequality and Average 
Cost per Uptake of a Japanese Government Intervention,” International Journal of Cancer 133 (2013): 972–
83. 
14 HSCIC, “Cervical Screening Programme England 2012–2013,” 2013, http://www.hscic.gov.uk/ 
searchcatalogue?productid=12601&q=title%3a+cervical+screening+programme&sort=Relevance&size=10
&page=1#top. 
15 D. Forman et al., “Global Burden of Human Papillomavirus and Related Diseases” Vaccine 30 (2012): 
F12–23. 
16 Yoshikawa et al., “Efficacy of Quadrivalent Human Papillomavirus (types 6, 11, 16 and 18) Vaccine 
(GARDASIL) in Japanese Women Aged 18–26 Years,” 465–72. 
  THE HPV VACCINATION IN JAPAN | 3 
                                                 
Figure 1. Estimated Age-standardized Incidence and Mortality Rates for Women in 
Japan17 
 
cervical cancer cases could be reduced by 73 percent if all 12-year-old girls in Japan 
were vaccinated.18  
Cervarix® and Gardasil® vaccines, which both 
protect against HPV types 16 and 18, were licensed 
in Japan in 2009 and 2011, respectively. From 2009, 
Cervarix® was partly funded by the Suginami local 
government. By April 2010, 32 of 1,747 local 
governments had decided to provide funding for the 
HPV vaccine.19 In October 2010, the central and local 
governments launched a temporary funding 
program and in April 2013, the HPV vaccine was included in the National 
Immunization Program (but was optional) and given for free. According to Asahi 
17 International Agency for Research on Cancer, “GLOBOCAN 2012: Estimated Cancer Incidence, Mortality 
and Prevalence Worldwide in 2012,” http://globocan.iarc.fr/Pages/Map.aspx#. 
18 R. Konno et al., “Cervical Cancer Working Group Report,” Japanese Journal of Clinical Oncology 40 
(2010): i44–i50. 
19 T. Uehara and K. Asami, “Vaccine financing in local governments,” Asahi Shimbun (Kansai regional 
edition), March 25, 2010. 
Given the recognized 
importance of the human 
papillomavirus in causing 
multiple cancers, it is 
critical not to lose public 
trust in this proven vaccine. 
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Shimbun, by June 2013, an estimated 8.29 million people in Japan had received the 
HPV vaccine.20 
On June 14, 2013—one day after the WHO declared the HPV vaccine safe21—the 
Japanese Ministry of Health, Labor, and Welfare (MHLW) issued a nationwide notice 
that while the HPV vaccine could still be given for free to girls aged 12 to 16, it should 
neither be proactively recommended nor promoted. Mariko Momoi, who chairs the 
panel at the MHLW, stated, “It is necessary to gather information immediately to 
accurately grasp how often (the side effects) are occurring.”22 A large press conference 
was held by the Vaccine Adverse Reactions Review Committee (VARRC) the same day, 
lasting over an hour, and featured girls who alleged to have been affected adversely 
by the vaccine with claims of convulsions, seizures, severe headaches, and partial 
paralysis.23 
In suspending its recommendation, the MHLW declared that it would investigate the 
reported cases, but as of April 2014, no conclusion has been reached. Because of the 
government’s nearly complete silence on its investigative process, other actors have 
filled the public information void. 
Anti-vaccination groups, as well as associations for parents of cervical cancer 
vaccination “victims,” have gained strength and public attention both locally and 
globally. One of the groups is headed by a parent who claims that her daughter, after 
vaccination with Cervarix®, lost the ability to walk and is now in a wheelchair.24 
Parents of another girl tried to claim compensation for suspected complex regional 
pain syndrome (CRPS). The national government refused because the vaccination was 
not yet in the National Immunization schedule. The local government of Suginami 
also initially refused to provide compensation for the family, but after the case was 
reported at a local assembly meeting in April 2013 and the victims’ group criticized 
the local government, intense media scrutiny prompted Suginami to agree to provide 
compensation (although this has not been paid yet).25 The public perceived this as an 
admission of guilt, and the issue became a tipping point for current anti-HPV vaccine 
sentiment. 
Concerns about the HPV vaccine have also spread through Japanese social networks. 
Toshie Ikeda, a female politician, is secretary-general of the Nationwide Cervical 
Cancer Vaccine Victim Liaison Committee, which is a victim support group. She uses 
her Twitter account and Facebook page to promote the group’s concerns.26 The 
20 Editorial, “HPV Vaccine Raises Questions,” Japan Times, June 14, 2013, http://www.japantimes.co.jp/ 
opinion/2013/06/14/editorials/hpv-vaccine-raises-questions/. 
21 WHO, “Update on human papillomavirus vaccines,” June 2013, http://www.who.int/vaccine_safety/ 
committee/topics/hpv/Jun_2013/en/index.html. 
22 “Cervix Vaccine Issues Trigger Health Notice,” Japan Times, June 15, 2013, http://www.japantimes.co.jp/ 
news/2013/06/15/national/cervix-vaccine-issues-trigger-health-notice/#.Uue5qdLFIdU. 
23 “Victims Hit Cervical Cancer Vaccines,” Japan Times, August 24, 2013, http://www.japantimes.co.jp/ 
news/2013/08/24/national/victims-hit-cervical-cancer-vaccines/#.Uue9kNLFIdU. 
24 Editorial, “HPV Vaccine Raises Questions.” 
25 子宮頸がんワクチン重い副反応 中学生、長期通学不能, Apital Asahi, March 8, 2013, 
http://apital.asahi.com/article/news/2013030800002.html. 
26 Hino Councillor Rie Ikeda Official Website, 日野市議会議員 池田利恵 公式ホームページ, 2014, 
http://ikedatoshie.com/. Additional stakeholders involved in the issues surrounding the withdrawal of the 
HPV vaccination recommendation include the MHLW Adverse Reaction Review Committee (副反応検討部
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Table 1. Major Events in Japan Related to the HPV Vaccine (2009–2013) 
 
absence of any media watchdog in Japan and relatively lax libel laws mean that 
newspapers, news programs, social networks, and victim support groups are able to 
publish unverified stories and videos of girls who claim to suffer from adverse events 
following HPV vaccination.27 
MHLW has added a page on its website (last updated on June 21, 2013) with a Q&A 
about the HPV vaccine, including a section on the safety of the vaccine28 and issued 
会) and the Japanese Expert Board for the Eradication of Cervical Cancer, the leading organization in 
Japan promoting social activities for cervical cancer prevention through screening and vaccination. The 
organization makes proposals and provides information to the Ministry of Health, Labor, and Welfare, 
local governments, and media. They contributed to the approval of the HPV vaccine in Japan in 2009, but 
they are not trusted by some members of the public as they are said to have links with the 
pharmaceutical industry. Other stakeholders are Japan’s Ministry of Education, Culture, Sports, Science 
and Technology (MEXT) and the National Institute of Infectious Diseases (NIID). 
27 A. Gamble and T. Watanabe, A Public Betrayed: An Inside Look at Japanese Media Atrocities and Their 
Warnings to the West (Washington, DC: Regnery, 2004). 
28 Ministry of Health, Labor, and Welfare, 般の方向けの情報, 2013, http://www.mhlw.go.jp/ 
bunya/kenkou/kekkaku-kansenshou28/qa_hpv.html. 
October 2009 
Cervarix® licensed in Japan. 
(Gardasil® was licensed in July 
2011.) 
March 2010 
After HPV vaccination, 3 girls 
complain of CRPS and 9 from 
chronic pain. 
April 2010 
32 of 1,747 local governments 
were providing funding for the 
HPV vaccine. 
October 2010 
Central and all local 
governments launch a temporary 
funding program. 
March 8, 2013 
Asahi newspaper press report of 
50 girls suffering from CRPS and 
100 absent from school after 
receiving the HPV vaccine. 
March 10, 2013 
Adverse events reported on TV 
news. 
March 25, 2013 
Press conference by “victim” 
group showing videos of girls 
suffering from walking 
disturbances and seizures, which 
was also posted on YouTube. 
April 1, 2013 
HPV vaccine included in the 
National Immunization Program 
(NIP). Optional and given for 
free. 
April 13, 2013 
Suginami local government 
announces its budget for the next 
fiscal year. This included 
compensation claimed by the 
parents of a girl with suspected 
CRPS following HPV vaccination. 
Case reported at local assembly 
meeting. 
May 19, 2013 
Another press conference by 
victim group. 
June 13, 2013 
WHO Global Advisory Committee 
on Vaccine Safety report released 
stating HPV vaccine is safe. Not 
reported in Japanese media. 
June 14, 2013 
Second joint meeting of the 
Vaccine Adverse Reactions 
Review Committee (VARRC). 
MHLW decided to temporarily 
suspend recommendation of HPV 
vaccine. 
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guidance to health care professionals.29 However, despite these laudable efforts to 
create more positive awareness of the vaccine’s safety, the absence of a government 
decision has enabled the spread of uncertainty and distrust. 
Contributing to Distrust: Japan’s Prior Experience with 
Vaccine Programs 
Japan’s prior experience has contributed to distrust of the pharmaceutical industry, 
including falsified Novartis data in an Alzheimer’s disease study.30 There is also a 
history of vaccine confidence issues in Japan related to adverse events following 
immunization.31 The Japanese government handled two past vaccine controversies—
the measles, mumps, and rubella (MMR) vaccine and Prevenar and Act-HIB—in very 
different ways: 
• The Japanese-manufactured MMR vaccine was introduced in 1989 and 
suspended in 1993 following high rates of aseptic meningitis associated with a 
component of the vaccine.32 Subsequently, measles, mumps, and rubella 
vaccines were given separately. In 1994, major changes were made to Japan’s 
immunization law: all childhood immunizations were no longer mandatory. 
Individuals were given “strong recommendations” to get the vaccine, but it 
would be their choice.33 By 2005, compared to measles (90–100 percent) and 
rubella (50–60 percent), the uptake of mumps vaccine was low in Japan at 30 
percent.34 In 2006, the MR (measles and rubella) combined vaccine was 
introduced to the National Immunization Program (NIP) with national 
government funding but adult males were not targeted for rubella vaccination. 
In 2011, MR vaccine coverage was high at 95.3 percent at age 1 year and 81.4 
percent at age 17–18 years. However, the reintroduction of the mumps vaccine 
into the NIP remains unresolved decades later and an outbreak of rubella in 
Japan involved 5,442 cases reported between January 1 and May 1, 2013, 
mostly in men aged over 20.35 
• In contrast, in March 2011 the MHLW suspended Pfizer’s Prevenar against 
meningitis and pneumonia and Sanofi’s Act-HIB against Haemophilus 
influenzae type b, following fears that the vaccines caused the deaths of four 
29 Ministry of Health, Labor, and Welfare, 子宮頸がん予防ワクチンの接種を受ける皆さまへ, 2013, 
http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/leaflet_h25_6_01.pdf. 
30 Agence France-Presse, “Novartis under fire over false Japanese drug data,” The Local (Stockholm), July 
12, 2013, http://www.thelocal.ch/20130712/novartis-under-fire-over-false-drug-data; Agence France- 
Presse, “Pharmaceutical Firms Accused of Falsifying Data in Major Alzheimer's Study,” Business Insider, 
January 10, 2014, http://www.businessinsider.com/pharmaceutical-firms-accused-of-falsifying-data-in-
major-alzheimers-study-2014-1. 
31 H. J. Larson and D. L. Heymann, “Public Health Response to Influenza A (H1N1) as an Opportunity to 
Build Public Trust,” Journal of the American Medical Association 303 (2010): 271–72. 
32 M. Kimura et al., “Adverse Events Associated with MMR Vaccines in Japan,” Acta paediatrica japonica 
38 (1996): 201–11. 
33 G. Harumi and T. Hiroshi, “Why Is Measles Still Endemic in Japan?” The Lancet 364 (2004): 328–29. 
34 H. Honda, Y. Shimizu, and M. Rutter, “No effect of MMR withdrawal on the incidence of autism: a total 
population study,” Journal of Child Psychology and Psychiatry 46 (2005): 572–79. 
35 Centers for Disease Control and Prevention, “National and State Vaccination Coverage among 
Adolescents Aged 13–17 Years—United States, 2012,” Morbidity and Mortality Weekly Report 62, no. 34 
(August 30, 2013): 685–93, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6234a1.htm#Fig1. 
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infants. The vaccines were reintroduced a few weeks later after it was proven 
that the vaccines did not cause the deaths.36 
International Perception of the HPV Controversy in Japan 
WHO responded to the Japanese government’s decision to suspend recommendation 
of the HPV vaccine with an update on human papillomavirus vaccines in their Global 
Advisory Committee on Vaccine Safety (GACVS) report (June 
2013), which states that  
There is little reason to suspect the HPV vaccine [of side 
effects], given its growing use worldwide in the 
absence of a similar signal from elsewhere. 
Recognizing the public concerns voiced, the Committee 
urges careful documentation of each case and a 
thorough search for a definitive diagnosis by medical 
specialists in order to best guide treatment. 37 
Thanks to the Internet and social media, news of the Japanese 
government’s withdrawal of its active recommendation for 
the HPV vaccine has reached a global audience—oftentimes 
with the facts misrepresented or obscured. To give just one example, a story posted on 
the U.S.-based Examiner.com alleging that the Japanese government has “withdrawn 
administration” of vaccines against HPV was reposted on a Kenyan news site, 
Lifestyle,38 the Catholic Philippines Facebook page,39 and the New Illuminati Facebook 
page.40 The ambiguity in the decision to suspend “active recommendation” of the 
vaccine—but not the “administration” of the vaccine—has allowed for multiple 
interpretations and misinterpretations. 
In the United States, several anti-vaccine websites, such as Age of Autism, quote a 
report written by Dr. Sataro Sato, a Japanese internist and cardiologist, which details 
numbers and types of adverse events following the vaccine, including brain damage.41 
Articles also provide petitions urging abolition of the vaccine for readers to sign, to be 
36 K. Matsuyama, “Japan Drug Panel Finds No Link between Child Deaths, Pfizer, Sanofi Shots,” 
Bloomberg, March 8, 2011, http://www.bloomberg.com/news/2011-03-08/japan-drug-panel-finds-no-link-
between-child-deaths-vaccination.html. 
37 WHO, “Global Advisory Committee on Vaccine Safety, Report of meeting held 12–13 June 2013,” 
http://www.who.int/vaccine_safety/committee/reports/Jun_2013/en/. 
38 K. Kaniaru, “Japan stops cancer vaccines as World Health Organization put in sharp focus,” The 
Standard (Nairobi), July 14, 2013, http://www.standardmedia.co.ke/lifestyle/article/2000088338/japan-
stops-cancer-vaccines-as-who-put-in-sharp-focus. 
39 Catholic Philippines, “World Health Organization Accused of Promoting Vaccines to Benefit 
Manufacturers,” Facebook, July 17, 2013, https://www.facebook.com/catholicph/posts/177436002428819. 
40 New Illuminati, “Japan stops cancer vaccines as World Health Organization put in Sharp Focus: 
Gardasil & Cevarix Too Dangerous and Ineffective,” Facebook, July 16, 2013, https://www.facebook.com/ 
the.new.illuminati/posts/10151799297344560; J. Stokowski-Bisanti, “World Health Organization Accused 
of Promoting Vaccines to Benefit Manufacturers,” Examiner.com, July 14, 2013, http://www.examiner. 
com/article/world-health-organization-accused-of-promoting-vaccines-to-benefit-
manufacturers#sthash.WXd8O43w.gbpl. 
41 “SaneVax Reports on Japan's Struggle with HPV Vaccination Injuries,” Age of Autism, August 26, 2013, 
http://www.ageofautism.com/2013/08/sanevax-reports-on-japans-struggle-with-hpv-vaccination-
injuries.html. 
The global coverage of 
Japan’s suspension of 
its HPV vaccine 
recommendation has 
been largely 
applauded by the anti-
vaccination groups 
but has baffled the 
global scientific 
community. 
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handed to the Japanese minister of health, Norisha Tamura. Authors inaccurately 
describe ”the virtually non-existent risk posed by being ‘infected’ with so-called 
carcinogenic HPV”42 and provide links to the 2013 Japanese press conference that 
shows videos of girls suffering from walking disturbances and seizures.43 An article 
on PR Web stated, “We wonder why the CDC and FDA are pushing Gardasil so strongly 
when health ministries in other countries are expressing concern.”44 
Most of the anti-vaccine sites analyzed by the authors of this paper contain long lists 
of anti-HPV vaccine comments by readers who state that manufacturers and the 
government are corrupt and that the Japanese health ministry does not trust the HPV 
vaccines.45 
In short, Japan’s suspension of the HPV vaccine recommendation has been largely 
applauded by the anti-vaccination groups, while it has baffled the global scientific 
community.46 Although anti-HPV vaccine sentiment is not widely spread on 
mainstream media, it has spread and been reinforced through social networks such as 
those mentioned above. 
HPV Vaccine Country Case Studies 
Japan is not alone in confronting reported adverse events following HPV vaccination. 
Concerns have been raised around the HPV vaccine in many countries, including 
India, the United Kingdom, France, and Australia (see Table 2). Like all vaccines and 
medicines, the HPV vaccine carries risks of adverse events, but they are generally 
minor; and most reported adverse events following immunization (AEFIs) are 
ultimately found to lack a causal connection. Nonetheless, whether the reported AEFIs 
are minor or serious, real or perceived, prompt and appropriate responses are critical 
to sustaining and rebuilding the public’s trust in the vaccine. 
In India, initial concerns were about the target population for the HPV vaccination 
demonstration project; the relevance, safety, and cost-effectiveness of the HPV 
vaccine; and distrust of the pharmaceutical industry.47 When advocacy groups were 
ignored, they intensified their efforts, culminating on World Health Day—April 7, 
2010—when 68 public health organizations and professionals organized a press 
conference to highlight their concerns regarding the HPV vaccines and issued another 
“Memorandum to the Health Minister on World Health Day Opposing HPV 
42 “HPV Vaccines Exposed: Subterfuge in a Syringe?,” Dprogram.net, November 9, 2013, 
http://dprogram.net/2013/11/09/hpv-vaccines-exposed-subterfuge-in-a-syringe/. 
43 Mahorobajapan, 子宮頸がんワクチン接種被害者映像 副反応のリスク, YouTube, April 9, 2013, 
http://www.youtube.com/watch?v=GRy6SYtCY1M&list=PLVamxbwCqPUi5TqaxPKbV15hciWNMBiYj. 
44 “HPV Vaccine: Israel Health Ministry Considers Cancelling Vaccination Due to Side Effects,” Prweb.com, 
September 4, 2013, http://www.prweb.com/releases/2013/9/prweb11084444.htm.  
45 “SaneVax Reports on Japan's Struggle with HPV Vaccination Injuries”; N. Erickson, “HPV Vaccines: 
Japan Leads the Way,” Robert Scott Bell Show, June 24, 2013, http://www.robertscottbell.com/ 
government/hpv-vaccines-japan-leads-the-way-by-norma-erickson/. 
46 S. Gilmour et al., “HPV Vaccination Programme in Japan,” The Lancet 382 (2013): 768; N. Erikson, “Japan 
and the HPV Vaccine Controversy,” Stranger in a Strange Land (blog), April 10, 2014, 
http://mnhopkins.blogspot.co.uk/2014/04/japan-and-hpv-vaccine-controversy-by.html?m=1. 
47 H. J. Larson, P. Brocard, and G. Garnett, “The India HPV-Vaccine Suspension,” The Lancet 376 (2010): 
572–73. 
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Vaccinations,”48 which was available to the general public through the Internet. The 
April memo called for the immediate halt of the HPV vaccine demonstration projects 
and an inquiry into, and compensation for, the reported side effects and alleged 
vaccine-related deaths of four girls who participated in the study.49 The government 
immediately suspended the HPV vaccination demonstration project, despite none of 
the deaths being attributed to the vaccination. This demonstrates that providing 
information for the public to make choices regarding vaccination is essential in 
preventing the spread of rumors generated by insufficient information. 
In the United Kingdom, following reports of a young girl’s death after receiving an 
HPV vaccination, the government investigated and responded within 24 hours, 
clarifying that the vaccine did not cause the girl’s death. The rapid engagement with 
the media and the public was crucial to containing the spread of further negative 
media and loss of public confidence.50 
In France, contradictory reports were released in response to a young woman’s 
complaint about an AEFI, although the vaccine continues to be administered under 
the National Immunization Program and recommendations for vaccination 
continue.51 
In Australia, positive and transparent information about the HPV vaccine was 
strengthened following the adverse events experienced by several dozen Melbourne 
school girls. The state government funded a new service, SAEFVIC (Surveillance of 
Adverse Events Following Vaccination in the Community) in April 2007.52 The HPV 
vaccine was not suspended. 
 
 
 
 
48 S. Azad, “Memorandum to the Health Minister on World Health Day Opposing HPV Vaccinations,” April 
7, 2010, http://samawomenshealth.wordpress.com/2010/04/08/memorandum-to-the-health-minister-on-
world-health-day-opposing-hpv-vaccinations/; L. C. Botha, “Breaking News: Organizations in India 
successfully halt HPV vaccination program,” Holy Hormones Journal, April 7, 2010, http://holyhormones. 
com/sister_song/breaking-news-organizations-in-india-successfully-halt-hpv-vaccination-program/. 
49 R. Sankaranarayanan, “HPV Vaccination: The Promise & Problems,” Indian Journal of Medical Research 
130 (2009): 322. 
50 WHO, “Case Study C: How a Potential HPV Vaccination Crisis Was Averted,” http://www.vaccine-safety-
training.org/c-serious-aefi-day-1.html. 
51 L. Clavreul and E. Cazi, “Des Experts font le lien entre Gardasil et Sclérose en Plaques,” Le Monde 
(Paris), November 24, 2013, http://www.lemonde.fr/sante/article/2013/11/24/premiere-plainte-contre-le-
vaccin-anticancer-gardasil_3519409_1651302.html; “Santé: Le Vaccine Gardasil Bientôt Visé par Trios 
Nouvelle Plaintes,” La Parisienne (Paris), November 24, 2013, http://www.leparisien.fr/ 
laparisienne/sante/sante-le-gardasil-au-coeur-d-une-plainte-24-11-2013-3344849.php; Sanofi Pasteur MSD, 
“Sanofi Pasteur MSD Rejects Opinion of Regional French Compensation Group in Gardasil Vaccination 
Claim,” media statement, November 25, 2013, https://www.spmsd.co.uk/upload/public/Files/10/ 
Final%20SPMSD%20Media%20Statement_Gardasil%20FR.pdf.  
52 J. P. Buttery et al., “Mass Psychogenic Response to Human Papillomavirus Vaccination,” Medical Journal 
of Australia 189 (2008): 261–62. 
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Table 2. HPV Vaccine Concerns in Japan, India, United Kingdom, France, and Australia 
Country Date of 
licensing  
Date of 
NIP 
inclusion  
Date and prompters of 
vaccine concerns  
When and what was the 
government response?  
 Japan October 
2009 
April 2013  April 2013: Family of alleged 
affected girl to be given 
compensation by Suginami 
local government over 
reported “side effects” of 
HPV vaccine 
June 14, 2013: Government 
suspends HPV vaccination 
recommendation. 
India 
 
July 2008 Not yet 
included 
October 2009: Public 
criticism of HPV vaccine 
demonstration project, 
vaccine safety concerns, 
costs, and ethical concerns. 
April 2010: Press conference 
and memorandum to health 
minister highlighting 
previous concerns and four 
deaths associated temporally 
with HPV vaccination. Public 
interest litigation initiated. 
April 2010: Government suspends 
HPV vaccination demonstration 
project. 
United 
Kingdom 
June 2006 September 
2008 
September 28, 2009: Young 
girl in Coventry collapses 
and dies soon after the first 
dose of HPV vaccine 
Evening of September 28, 2009: UK 
Department of Health acts quickly 
to inform the media and the public 
that the death was not due to the 
HPV vaccine. No vaccine 
suspension. 
France July 2007 October 
2007 
2010: Teenage girl develops 
vertigo, vomiting, temporary 
loss of sight and use of legs, 
and facial paralysis two 
months following HPV 
vaccination. In 2013 she files 
a criminal complaint against 
Sanofi Pasteur MSD and 
France's medicines safety 
agency (ANSM) and holds a 
press conference explaining 
her AEFI  
November 2013: The chair of the 
national committee states there is 
no evidence to link Gardasil with 
serious autoimmune conditions, 
but the Commission régionale de 
conciliation et d'indemnisation des 
accidents médicaux (CRCI) 
acknowledges a link between 
pathology and vaccination. Sanofi 
Pasteur issues a press release 
supporting the safety profile of the 
HPV vaccine and challenges the 
CRCI statement. No vaccine 
suspension. 
Australia April 
2007 
April 2007  May 2007: 720 girls receive 
HPV vaccination at a 
Melbourne girl’s school. 
26 girls develop symptoms 
including dizziness, syncope, 
and neurological complaints. 
Four taken to hospital.  
Radio interviews with the then-
federal health minister and the 
Victorian state premier. The state 
government funded a new service, 
SAEFVIC (Surveillance of Adverse 
Events Following Vaccination in 
the Community) in April 2007. No 
vaccine suspension. 
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The Rumor Mill’s Corrosive Impact 
In analyzing this issue, it is important to acknowledge the corrosive effects of rumors 
and their impact on public trust. According to experts in rumor psychology, rumors 
help people make sense of the world and offer an initial explanation for anxiety-
provoking information and events.53 The longer situations of uncertainty and anxiety 
persist, the easier it becomes for rumors to spread and the more difficult they become 
to counteract.  
Dr. Barbara Reynolds, an expert in governmental risk communication at the U.S. 
Centers for Disease Control and Prevention (CDC), highlighted five potentially 
disastrous mistakes in public health communication: mixed messages from multiple 
experts; information released late; paternalistic attitudes; not countering rumors and 
myths in real time; and public power struggles and confusion. To avoid these 
mistakes, the CDC recommends that governments should:  
1. Be the first to provide information. Don’t withhold factual information. If this 
is done, it leaves a vacuum that may be filled by people who don’t have the 
public’s best interest at heart. 
2. Be accurate with information. Accuracy is important, and so is responding 
quickly. These aspects can sometimes be in tension. The government should 
release factual information quickly and state what is being done to get 
additional information. The public is better served by receiving reliable 
information sequentially than a fully complete report months after an event.  
3. Be credible. Governments should not withhold information to avoid 
embarrassment or a possible public “panic” that rarely if ever happens. 
Uncertainty is worse than not knowing; rumors are more damaging than hard 
truths.  
4. Express empathy. When government officials acknowledge in words what 
people are feeling, it builds trust. Officials can say, “We understand why this 
might be concerning.” This should be followed by information that addresses 
public concerns. 
5. Promote action. Giving people positive steps they can take, such as, “Talk to 
your doctor,” or “You can find out more on this website,” encourages them to 
feel more in control and empowered.  
6. Show respect. In particular, governments should never be paternalistic, 
either withholding information from the public to “protect” them or dismissing 
concerns. 
 
 
53 N. DiFonzo and P. Bordia, Rumor Psychology: Social and Organizational Approaches (Washington, DC: 
American Psychological Association, 2006). 
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Conclusion and Recommendations 
In Japan, the withdrawal of the recommendation of the HPV vaccine, the agreed 
compensation to several girls from local governments, and rumors spread by social 
media have caused members of the public to distrust the vaccine. Even if the 
government renews its active recommendation, the climate of fear and uncertainty 
could hinder the success of the HPV vaccination program, which is especially 
worrying due to low rates of Pap tests and high rates of cervical and oropharyngeal 
cancer in Japan. The Japanese government must act quickly to reassert control of the 
message, or risk losing a historic opportunity to save the lives of girls and women in 
the years ahead. 
First, the government of Japan must engage in an open and ongoing way with the 
media, key stakeholders, and the public to provide clear information regarding the 
process currently underway (i.e., research regarding safety profiles of the vaccine, 
especially for Japanese people). 
Moving forward, steps to restore public confidence and trust should include: 
• Providing the public with a clear and concise decision, restoring an active 
recommendation for HPV vaccination, supported by evidence including 
statistics on the vaccine’s safety and highlighting the successful implementation 
and high uptake rates of the vaccine in other countries. Organizations such as 
the Brighton Collaboration based in Switzerland and the Strategic Advisory 
Group of Experts (SAGE) based in the United States, United Kingdom, and 
Indonesia, can aid public health authorities in making decisions surrounding 
vaccination, based on large databases and safety research standards. (See 
recommended links to regional websites containing information about the HPV 
Vaccine in Appendix 3.) 
• Providing physicians, nurses, and other health care providers with accurate 
materials they can use with their patients to address concerns and questions. 
Among other things, this information should reinforce that: 
o While Pap tests are invaluable for detecting early signs of cervical 
cancer and other issues, they do not prevent the development of 
precancerous lesions from occurring; 
o HPV vaccination can also protect against oropharyngeal cancer and 
other life-threatening illnesses; 
o HPV vaccination does not cause sexual promiscuity; 
o HPV vaccination is important for reproductive health. This information 
can be disseminated at schools, in doctors’ surgeries and clinics and 
online through websites similar to Australia’s cancer council and social 
media (see Appendix 3). 
• Actively promoting HPV vaccination to parents (mothers in particular). 
Mothers are typically the family health care decisionmakers. They need to have 
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their questions and concerns addressed in order to feel comfortable taking 
their daughters to be vaccinated.  
• Advising that the HPV vaccine, like any other vaccine, may cause side effects 
but that these do not occur at a rate higher than other vaccines and that 
preventing cancer is far better than treating it. 
• Developing school-based vaccination programs, so that students do not have to 
miss class or find their own way to a medical clinic. School-based programs 
also allow for the engagement of parent-teacher associations, which can offer 
an important venue for dialogue and for cultivating parental buy-in. According 
to Fujiwara et al.,54 school-based vaccinations and public subsidies are the most 
effective method to improve HPV vaccination coverage.  
• Establishing a system that allows the public to express concerns and receive 
swift, evidence-based answers. 
As evident in Japan, if government support is lost, even if vaccination is provided for 
free, coverage rates can fall substantially. Therefore, once a decision has been made, 
the government should have a strong, evidence-based communications plan, enabling 
it to respond to public concerns or questions surrounding the HPV vaccine. 
54 H. Fujiwara et al., “Community-Based Interventions to Improve HPV Vaccination Coverage among 13- 
to 15-Year-Old Females: Measures Implemented by Local Governments in Japan,” PLoS One 8 (2013): 
e84126. 
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Appendix 1. Incidence of Cervix Uteri Cancer Globally 
(weighted mean of age-specific rates) (IARC 2012) 
 
 
N.B. Data for Japan estimated from national mortality by modeling, using incidence mortality ratios 
derived from recorded data in country-specific cancer registries. International Agency for Research on 
Cancer (IARC). 
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Appendix 2. Cancers, Other than Cervix Uteri, Associated 
with HPV Infection, Age-standardized (world standard) 
Incidence Rates per 100,000, 1978–2007, per 5-year Period, 
in Selected Cancer Registry Populations (all ages) 
 
 
Based on International Agency for Research on Cancer (IARC), Cancer Incidence in Five Continents, 
Volumes V to IX (Lyon, France: IARC, various years); Surveillance, Epidemiology, and End Results (SEER) 
Program, National Cancer Institute; and David Forman et al., “Global Burden of Human Papillomavirus 
and Related Diseases,” Vaccine 30, supp. 5 (November 2012), http://www.sciencedirect.com/science/ 
article/pii/S0264410X12010808 - bib0125. Data are for males (M) and females (F) combined for 
oropharynx and anus; oropharynx does not include base of tongue nor tonsils. ASR (W): Age-
standardized (world standard) rate.  
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Appendix 3. Recommended Links to Regional Websites 
Containing Information about the HPV Vaccine 
 
Europe 
European Cervical Cancer Association 
http://www.ecca.info/fileadmin/user_upload/HPV_Vaccination/ECCA_HPV_Vaccination
_April_2009.pdf 
 
United Kingdom  
National Health Service (NHS)  
http://www.nhs.uk/Conditions/vaccinations/Pages/hpv-human-papillomavirus-
vaccine.aspx 
http://www.nhs.uk/Conditions/vaccinations/Pages/hpv-vaccine-cervarix-gardasil-side-
effects.aspx 
 
Australia 
Cancer Council Australia  
http://www.hpvvaccine.org.au/the-hpv-vaccine/has-the-program-been-successful.aspx  
 
New Zealand 
Ministry of Health 
http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-
immunisation-programme/hpv-vaccine 
 
United States 
Centers for Disease Control and Prevention (CDC) 
http://www.cdc.gov/vaccinesafety/vaccines/HPV/Index.html 
 
Canada 
Public Health Agency of Canada 
http://www.phac-aspc.gc.ca/std-mts/hpv-vph/hpv-vph-vaccine-eng.php 
Immunize BC 
http://www.immunizebc.ca/diseases-vaccinations/hpv 
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